Polymerase chain reaction (PCR) genotyping of malaria parasites in drug efficacy trials helps differentiate reinfections from recrudescences. A combination therapy trial of one (n ¼ 115) or three (n ¼ 117) days artesunate (1AS, 3AS 4 mg/kg/day) plus sulphadoxine-pyrimethamine (SP) vs. SP alone (n ¼ 153) was conducted in Mbarara, a mesoendemic area of western Uganda. 
Introduction
The World Health Organization (WHO) in vivo antimalarial efficacy testing protocol is instrumental in assessing and monitoring the emergence and extent of parasite resistance to antimalarial drugs (WHO 1973) . The current WHO in vivo protocol for high transmission areas recommends 28 days of follow-up, stipulating that recurrent parasites should be genotyped by polymerase chain reaction (PCR) to distinguish recrudescent from new infections (WHO 2003 (WHO , 2006 . The ability to discriminate newly acquired infections by comparison of baseline and recurrent parasite genotypes allows a more accurate estimate of the true levels of treatment failures. However, because of resource constraints in malaria-endemic areas, genotyping all recurrent infections, particularly in large trials, is expensive and may not be feasible. To compensate for such limited recourses, correction of treatment outcome could be made by only genotyping post-day 14 recurrences whilst assuming that most recurrent parasites before or on day 14 are likely to be due to recrudescences. This strategy was adopted for a series of WHO/TDR coordinated clinical trials assessing artesunate in combination with standard antimalarial drugs for the treatment of paediatric falciparum malaria in several African countries, including Burkina Faso, Gabon, The Gambia, Sao Tomé, Senegal, Uganda, Malawi and Kenya (von Seidlein et al. 2000; Adjuik et al. 2002 Adjuik et al. , 2004 Gil et al. 2003; Obonyo et al. 2003; Priotto et al. 2003; Sirima et al. 2003) . We report the PCR-defined reinfection rates on days 7, 14, 21 and 28 in the Ugandan efficacy trial (Priotto et al. 2003) and assess their effect on the efficacy outcome.
Methodology
A 28-day antimalarial combination efficacy trial was conducted in Mbarara District Hospital in Uganda, an area of seasonal, mesoendemic malaria using artesunate (AS 4 mg/kg/day)/placebo plus standard dose sulphadoxine-pyrimethamine (SP) for treating acute uncomplicated, falciparum malaria in children: SP alone (n ¼ 168), SP + AS 3 days (n ¼ 126), SP + AS 1 day (n ¼ 126). The trial profile and clinical findings are detailed in Priotto et al. (2003) .
PCR amplification
Blood for PCR analysis was collected onto Isocode stix Ò (Schleicher & Schull, Dassel, Germany) on days 0, 7, 14, 21 and 28 and DNA extracted following the manufacturer's instructions (i.e. washing and boiling of Isocode stix Ò ). Plasmodium falciparum in paired samples collected on day 0 and any day (7, 14, 21 or 28) of recurrent parasitaemia were genotyped by analysing the glurp, msp 1 and 2 loci. PCR amplifications were performed at the Ifakara Health Research and Development Centre (IHRDC) laboratory using an MJ Thermal Controller PTC-100 TM (MJ Research Inc., Watertown, USA). Primary glurp, msp1 and msp2 PCR reactions were multiplexed whereas nested PCR amplifications were performed separately for each locus. The primary and nested amplifications were carried out in 20 and 30 ll reaction volumes using 5 ll of template DNA and 2 ll of primary PCR product, respectively. All oligonucleotide primers and reference DNA were obtained from the Malaria Research and Reference Reagents Resource Centre (MR4). The oligonucleotide primers have been described elsewhere (Felger et al. 1994; Irion et al. 1998; Snounou et al. 1999) . Temperature cycling parameters were: initial denaturation at 94°C for 5 min followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 55°C for 2 min (for primary PCR) or 58°C for 2 min (for nested PCR) and extension at 72°C for 2 min. The last extension cycle was prolonged for 10 min. msp2 PCR product (10 ll) was digested with 3 U of HinfIII for 2.5 h at 37°C and the resulting fragments were resolved on 10% polyacrylamide gels. The glurp and msp1 PCR products were directly resolved on 2% agarose gel. For better comparison of fragments paired samples were loaded onto the gels side by side. Gels were stained with ethidium bromide, visualized under UV illumination, photographed and discrimination made as described.
Definitions of recrudescent and new infections and data analysis
A recurrent parasitaemia was classified as a recrudescence (true failure) if the following conditions were met: (i) all alleles of the three loci in the baseline and recurrent parasitaemia were identical, (ii) a sharing of baseline and recurrent alleles but with some missing alleles in the recurrent parasitaemia, and (iii) a sharing of baseline and recurrent alleles but with new alleles in recurrent sample that were not observed at baseline. A recurrent parasitaemia was classified as a new infection or treatment success, if the allelic pattern for any one of the loci differed completely between the baseline and recurrent samples (Snounou & Beck 1998) . The clinical and molecular genotyping data were analysed using stata v 8.0 (Stata Corporation Inc., Texas, USA)
Results
Of the 373 patients who completed the 28-day follow-up 190 had recurrent parasitaemias. All these recurrent parasitaemias were genotyped by PCR amplification to distinguish recrudescence from reinfection. Table 1 provides a summary of genotyping results per treatment arm. PCR was unresolved for 34 patients due to eight incomplete paired samples and failure to extract/amplify DNA on 26 recurrent samples. The proportions of new infections on days 7, 14, 21, 28 were 5 of 26 (19.2%), 24 of 51 (47.1), 29 of 50 (58%) and 19 of 29 (65.5%), respectively. The corresponding values for the recrudescences were 21 (80.8%), 27 (52.9%), 21 (42%), and 10 (34.5%). Figure 1 illustrates proportions of new and recrudescent infections on days 7, 14, 21 and 28. The ratios of proportions of new to recrudescent infections were 0.2 (19.2:80.8), 0.9 (47.1:52.9), 1.4 (58:42), and 1.9 (65.5:34.5), on days 7, 14, 21, and 28, respectively. The chi-square test for linear trend was 12.8 (P < 0.001), demonstrating a linear increase in the odds ratios on days 14, 21 and 28 compared with day 7. The frequencies of new infections increased The effect of the 29, pre-day 14, new infections is to lower the overall failure rate (all three arms combined) by 7.8% (29/373) by counting unresolved PCR data as failures, or by 8.6% (29/339), if unresolved PCR data are excluded.
Discussion
In the artesunate-based combination therapy trials conducted by WHO/TDR in Sub-Saharan African countries only post-day 14 recurrent parasitaemias were genotyped to distinguish recrudescent from new parasites and treatment failure rates adjusted accordingly. In the present study, we genotyped all recurrent parasitaemias observed on days 7, 14, 21 and 28 from one site, Mbarara, Uganda, in order to assess pre-and post-day 14 re-infection rates. We observed unexpectedly high frequencies of genotypically new infections on days 7 (approx. 19%) and 14 (approx. 47%). Although the entomological inoculation rate was not measured in this study, cumulative re-inoculations during follow-up have resulted in these new infections which represent an important fraction of the total number of recurrent parasitaemias. Given that the prepatent period for P. falciparum is 6-12 days, and that pyrimethamine has weak causal prophylactic activity, parasitaemias detected on days 7 or 14 after initial parasite clearance may represent early new infections. Therefore, the assumption that recurrent parasitaemias on days 7 and 14 in high transmission areas are due to recrudescence and should be excluded from genotyping assays may be erroneous. These findings strongly suggest that genotyping should also be conducted on recurrent parasitaemias recorded before and on day 14.
Characterizing these early recurrences may change substantially our appreciation of drug efficacy. By taking these new infections into account, the overall failure rate fell by approximately 7-8%. This change could have a profound effect on deciding drug policy if the efficacy of a given drug is not deemed to have reached a predefined threshold for changing drug policy. The using of PCR-corrected efficacy end points in malarial drug trials has become standard practice but there are variations in the way that the PCR data have been interpreted (Ranford-Cartwright et al. 1997; Brockman et al. 1999; Basco & Ringwald 2000; Magesa et al. 2001; Basco et al. 2002; Cattamanchi et al. 2003; Happi et al. 2004) . This calls for a standardized genotyping protocol for areas of intense malaria transmission.
It has been speculated that new infections might already be present during the clinical presentation but sequestered and not detected by PCR only to be picked up at the time of recurrence. Although this might indeed occur in a few cases, ample evidence exists that clinical episodes are less complex. A study by Irion et al. (1998) found that <2% of recrudescent genotypes were absent on day 0 but were detected on day 3. Similarly, Farnert and Bjorkman (2005) detected the same genotypes in consecutive samples obtained every 12 h for at least 3 days post-treatment in Swedish non-immune travellers who acquired falciparum malaria in Africa. These observations suggest that single time-point samples may reliably represent all subpopulations present prior to treatment. A further complication in the interpretation of paired genotype data arises from infections with new parasites possessing identical genotypes to those present on day 0, leading to an erroneous diagnosis of recrudescence. However, in endemic areas the probability of this occurrence is rather low and negligible when two or more discriminatory markers are being used. We believe this theoretical possibility is not an important consideration in the interpretation of our findings because we observed a high rate (approx. 33%) of new infections (different genotypes) within the first 14 days of follow-up.
In our study, laboratory failure to amplify/detect parasite genetic material in the recurrent samples was the main cause of the loss of genotyping data. This PCR failure is highly attributable to the low parasite densities in the recurrent samples coupled with a less invasive/rigorous DNA extraction method consisting of simple washing and boiling of the Isocode stix Ò . The performance and effective use of PCR genotyping will be detailed in a general report on the combination therapy trials that will be published separately.
The definition of drug-resistant malaria and the reporting of drug efficacy data are becoming more complicated with our better understanding of P. falciparum molecular genetics, seasonal variations in malaria transmission, drug pharmacokinetics (e.g. longer follow-up is required for long half-life drugs) and the intrinsic parasiticidal effects of antimalarial drugs (White 1998). Further studies are needed to assess the importance of genotyping recurrent parasitaemias observed between days 7 and 14 and how this might refine the current WHO definitions of late clinical and parasitological failures. More robust definitions will be beneficial to policy makers. 
